More Actinogen Medical Limited news
Actinogen Medical LimitedASX: ACW

TGA Regulatory Approval for Alzheimers Phase II Trial

Mar 7, 2017 at 10:52 PM EST · Issued by Actinogen Medical Limited

Filed with ASX · Mar 7, 2017 at 10:52 PM EST

On 6ix: 6ix.com/news/tga-regulatory-approval-for-alzheimers-phase-ii-trial

Actinogen Medical Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Actinogen Medical Limited on 6ix

Story so far

  • UK Regulatory Approval for Alzheimers Clinical Trial-XanADuFeb 10, 2017
  • FDA Approval to Commence Alzheimers Disease Clinical TrialJan 3, 2017
  • Significant Advance in Development of Alzheimers DrugDec 19, 2016

Earlier from Actinogen Medical

  • Actinogen Medical Financial ResultsFeb 27, 2017
  • UK Regulatory Approval for Alzheimers Clinical Trial-XanADuFeb 9, 2017
  • Xanamem Research Published in Prestigious Medical JournalFeb 8, 2017
  • Appendix 4C - quarterlyJan 22, 2017
  • FDA Approval to Commence Alzheimers Disease Clinical TrialJan 2, 2017

Later from Actinogen Medical

  • March Quarterly UpdateApr 25, 2017
  • First Patient Treated in Landmark Alzheimers Clinical TrialMay 15, 2017
  • First UK Site Goes Live in Global Alzheimers Clinical TrialMay 31, 2017
  • First US Patients Treated in Landmark Alzheimers TrialJun 21, 2017
  • June Quarterly UpdateJul 26, 2017
All Actinogen Medical news releases↗

Follow Actinogen Medical into a list and get an email when it puts out news.

Follow Actinogen Medical
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer